Table 2.
Myalgia characteristics in the treosulfan cohort and busulfan cohort.
| Characteristic | Treosulfan (n = 34) | Busulfan (n = 3) |
|---|---|---|
| Age at SCT (years, median (range)) | 12.2 (1.8–18.2) | 11.5 (10.9–17.2) |
| Sex (n: M/F) | 20/14 | 67/33 |
| Diagnosis for HSCT | ||
| Beta-thalassemia (%) | 15 (44) | – |
| Sickle cell disease (%) | 13 (38) | – |
| Inborn errors of immunity (%) | 1 (3) | – |
| Hematological malignancy (%) | 4 (12) | 3 (100) |
| Bone marrow failure (%) | 1 (3) | – |
| Conditioning | ||
| Treo-Flu-Thiotepa (%) | 28 (82) | – |
| Treo-Flu (%) | 5 (15) | – |
| Treo-Other (%) | 1 (3) | – |
| Bu-Flu-Clo (%) | – | 3 (100) |
| Location of pain | ||
| Leg (%) | 33 (97) | 3 (100) |
| Arm (%) | 28 (82) | 3 (100) |
| Knee / ankle (%) | 16 (47) | – |
| Elbow (%) | 9 (26) | – |
| Neck (%) | 9 (26) | – |
| Back (%) | 8 (24) | – |
| Shoulder (%) | 7 (21) | – |
| Foot (%) | 15 (44) | – |
| Hand (%) | 8 (24) | – |
| Duration of pain | ||
| ≤ 7 days (%) | 4 (12) | 1 (33) |
| 8–14 days (%) | 7 (20) | 2 (67) |
| 15–21 days (%) | 8 (24) | – |
| > 21 days (%) | 15 (44) | – |
| Medical intervention | ||
| Paracetamol/acetaminophen | 34 (100) | 3 (100) |
| NSAIDs | 4 (12) | 1 (33) |
| Tramadol | 32 (94) | 2 (67) |
| Opiate, oral | 5 (15) | 1 (33) |
| Opiate, intravenous | 21 (62) | 1 (33) |
| Antiepileptics (e.g. gabapentin, pregabalin) | 8 (24) | – |
| Other (e.g. ketamine, clonidine, benzodiazepines) | 13 (38) | 1 (33) |
| Pain severity | ||
| Step 1 (paracetamol) | 2 (6) | |
| Step 2 (paracetamol + tramadol) | 11 (32) | 1 (33) |
| Step 3 (addition of strong acting opiate) | 6 (18) | 1 (33) |
| Step 4 (addition of adjuvant medicines) | 15 (44) | 1 (33) |
Treo treosulfan, Flu fludarabine, Thio thiotepa, Bu busulfan, Clo clofarabine.